Strictly regular use of ivermectin as prophylaxis for COVID-19 leads to a 90%
reduction in COVID-19 mortality rate, in a dose-response manner: definitive results
of a prospective observational study of a strictly controlled 223,128 population from
a city-wide program in Southern Brazil.
Introduction
Ivermectin has been proposed as a potential prophylaxis and therapy for COVID-19 due
to its previously reported multi anti-viral [1-4], metabolic [5-10] and anti-inflammatory
[11-19] actions, with strong plausibility [20,21] and preliminary positive in-vitro, in-vivo
and epidemiological findings [22-24].
Based on the absence of therapeutical and preventive alternative options in 2,020,
and on the extensive, well-established safety profile and known absence or risks with
long-term use of ivermectin, a city-wide program in a city in Southern Brazil (Itajaí, state
of Santa Catarina) offered a medically-prescribed program of ivermectin as prophylaxis
for COVID-19 between July and December of 2020.
Previously, as resulted from the systematically collected data from this program,
we have shown that ivermectin use as prophylaxis for COVID-19 improved COVID-19
related-outcomes, leading to a 44% reduction in infection rate, 56% reduction in
hospitalization rate, and 68% reduction in mortality rates, employing propensity score
matching (PSM) to balance groups [25]
Find more at this link which is a PDF
https://www.researchgate.net/profile/Cadegiani-Flavio/publication/358386329_Strictly_regular_use_of_ivermectin_as_prophylaxis_for_COVID-19_leads_to_a_90_reduction_in_COVID-19_mortality_rate_in_a_dose-response_manner_definitive_results_of_a_prospective_observational_study_of_a/links/61ff2f341674b45977c9a985/Strictly-regular-use-of-ivermectin-as-prophylaxis-for-COVID-19-leads-to-a-90-reduction-in-COVID-19-mortality-rate-in-a-dose-response-manner-definitive-results-of-a-prospective-observational-study-of.pdf